Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the

Read the full 268 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE